

Notification:	HUM 7579
<u>Category:</u>	HCPCS - Drugs & Biologicals
Topic:	Louisiana Medicaid: HCPCS codes J1745, Q5103, Q5104, Q5109 and
	Q5121 – infliximab and its biosimilars
What is changing? /	For providers with a specialty other than home infusion therapy or
<b>Change Description:</b>	pharmacy, we limit reimbursement of charges for HCPCS codes J1745,
	Q5103, Q5104, Q5109 or Q5121 to no more than:
	• 37 units for a diagnosis of uveitis per date of service if billed for
	patients between ages 3–5
	• 63 units for a diagnosis of uveitis per date of service if billed for
	patients between 6–8
	• 94 units for a diagnosis of uveitis per date of service if billed for
	patients between 9–11
	• 148 units for a diagnosis of uveitis per date of service if billed for
	patients between 12–15
	• 125 units per date of service for a diagnosis of uveitis if billed for
	patients between 16–18
Why is Humana making this change?	The limitations above are established by the FDA-approved package
/ Change Reason:	insert and prescribing information and the pharmaceutical
	compendia.Note: The limitations described above are based on
	maximum dosages established in milligrams. If any units are denied,
	the provider may dispute the decision through the appropriate
	process. The provider may submit information, including medical
	notes showing the patient's body weight, that substantiates the
	medical necessity of the additional units.
<u>Language:</u>	<u>English</u>
<b>Impacted Products:</b>	Medicaid- Louisiana